ATE529750T1 - Stimulatorische autoantikörper gegen den pdgf- rezeptor als pathologische marker und therapeutisches target - Google Patents
Stimulatorische autoantikörper gegen den pdgf- rezeptor als pathologische marker und therapeutisches targetInfo
- Publication number
- ATE529750T1 ATE529750T1 AT06796239T AT06796239T ATE529750T1 AT E529750 T1 ATE529750 T1 AT E529750T1 AT 06796239 T AT06796239 T AT 06796239T AT 06796239 T AT06796239 T AT 06796239T AT E529750 T1 ATE529750 T1 AT E529750T1
- Authority
- AT
- Austria
- Prior art keywords
- pdgf receptor
- therapeutic target
- autoantibodies against
- pathological marker
- erk1
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
- G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rehabilitation Therapy (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70337705P | 2005-07-28 | 2005-07-28 | |
PCT/IT2006/000587 WO2007013124A2 (en) | 2005-07-28 | 2006-07-28 | Stimulatory auto-antibodies to the pdgf receptor as pathology marker and therapeutic target |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE529750T1 true ATE529750T1 (de) | 2011-11-15 |
Family
ID=37683748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06796239T ATE529750T1 (de) | 2005-07-28 | 2006-07-28 | Stimulatorische autoantikörper gegen den pdgf- rezeptor als pathologische marker und therapeutisches target |
Country Status (8)
Country | Link |
---|---|
US (2) | US20090221481A1 (de) |
EP (1) | EP1907851B1 (de) |
JP (1) | JP2009503493A (de) |
KR (1) | KR20080077347A (de) |
CN (1) | CN101517414A (de) |
AT (1) | ATE529750T1 (de) |
CA (1) | CA2616963A1 (de) |
WO (1) | WO2007013124A2 (de) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2122348B1 (de) * | 2007-01-25 | 2014-08-13 | Mariarosaria Santillo | Verfahren zur diagnose einer autoimmunkrankheit und zur identifizierung und isolierung stimulierender moleküle |
EP2598532B1 (de) | 2010-07-30 | 2017-07-12 | Gianluca Moroncini | Epitope des menschlichen pdgf-rezeptors zur bindung von menschlichen autoantikörpern, antikörper und ihre verwendung |
US20150355191A1 (en) * | 2012-07-11 | 2015-12-10 | Biomimetic Therapeutics, Llc | Cell-Based Assay for Neutralizing Antibodies |
WO2014016284A1 (en) * | 2012-07-23 | 2014-01-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for diagnosing scleroderma |
EP2917237A1 (de) * | 2012-11-09 | 2015-09-16 | Pfizer Inc. | Aus blutplättchen gewonnene wachstumsfaktor-b-spezifische antikörper sowie zusammensetzungen daraus und verwendungen davon |
WO2020037378A1 (en) * | 2018-08-24 | 2020-02-27 | The Flinders University Of South Australia | Detection of functional autoantibodies |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0325224B1 (de) * | 1988-01-22 | 1996-07-31 | ZymoGenetics, Inc. | Verfahren zur Herstellung von sekretierten Rezeptoranalogen |
US5268358A (en) * | 1988-12-08 | 1993-12-07 | Cor Therapeutics, Inc. | PDGF receptor blocking peptides |
CA2138932A1 (en) * | 1993-12-28 | 1995-06-29 | Masako Wagatsuma | Mutant proteins of human dna topoisomerase i |
JP3472048B2 (ja) * | 1995-10-09 | 2003-12-02 | 鐘淵化学工業株式会社 | 自己免疫疾患の診断薬 |
JP2004511802A (ja) * | 2000-10-17 | 2004-04-15 | ベッスト−テスト アンパーツゼルスカブ | 体液サンプル中の炎症の指標の直接的検出のためのアッセイ |
JP3455782B2 (ja) * | 2001-12-27 | 2003-10-14 | 学校法人慶應義塾 | 強皮症の診断薬 |
-
2006
- 2006-07-28 CN CNA2006800337752A patent/CN101517414A/zh active Pending
- 2006-07-28 KR KR1020087002211A patent/KR20080077347A/ko not_active Application Discontinuation
- 2006-07-28 AT AT06796239T patent/ATE529750T1/de not_active IP Right Cessation
- 2006-07-28 WO PCT/IT2006/000587 patent/WO2007013124A2/en active Application Filing
- 2006-07-28 US US11/996,541 patent/US20090221481A1/en not_active Abandoned
- 2006-07-28 CA CA002616963A patent/CA2616963A1/en not_active Abandoned
- 2006-07-28 JP JP2008523550A patent/JP2009503493A/ja active Pending
- 2006-07-28 EP EP06796239A patent/EP1907851B1/de active Active
-
2011
- 2011-09-28 US US13/247,127 patent/US20120252037A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20120252037A1 (en) | 2012-10-04 |
CA2616963A1 (en) | 2007-02-01 |
CN101517414A (zh) | 2009-08-26 |
EP1907851B1 (de) | 2011-10-19 |
JP2009503493A (ja) | 2009-01-29 |
WO2007013124A3 (en) | 2007-07-19 |
WO2007013124A8 (en) | 2007-09-27 |
US20090221481A1 (en) | 2009-09-03 |
KR20080077347A (ko) | 2008-08-22 |
EP1907851A2 (de) | 2008-04-09 |
WO2007013124A2 (en) | 2007-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120014T1 (el) | Αντισωματα συνδεσης πρωτοϊνιδιου και χρηση αυτων σε θεραπευτικες και διαγνωστικες μεθοδους για ασθενεια parkinson, ανοια με σωματα lewy και αλλες αλφα-συνουκλεϊνοπαθειες | |
BRPI0510274B8 (pt) | uso de um agente para tratar ou prevenir doença celíaca, composição farmacêutica compreendendo dito agente, método de diagnóstico de doença celíaca, ou suscetibilidade à doença celíaca, uso do dito agente para a preparação de um meio de diagnóstico e kit para realizar o dito método de diagnóstico | |
BRPI0519047A2 (pt) | mÉtodo para a produÇço de um agente de contraste marcador ou agente terapÊutico marcador, agentes de contraste marcadores e uso de agentes de contraste marcadores ou de agentes terapÊuticos marcadores | |
WO2006063093A3 (en) | Methods for diagnosis and treatment of crohn's disease | |
ATE529750T1 (de) | Stimulatorische autoantikörper gegen den pdgf- rezeptor als pathologische marker und therapeutisches target | |
EA200801071A1 (ru) | Способы и композиции для применения в целях лечения пациентов с положительным по аутоантителам заболеванием | |
LU93321I2 (fr) | Ibrutinib, ou un sel pharmaceutiquement acceptable de celui-ci | |
FR16C0021I2 (fr) | Azetidines en tant qu'inhibiteurs de mek et leur utilisation pour le traitement des maladies proliferatives | |
BR0210886A (pt) | Composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal | |
NZ609493A (en) | Diagnosis and treatments relating to th2 inhibition | |
MA34120B1 (fr) | Composition pharmaceutique | |
CY1118566T1 (el) | Διαγνωση με χρηση ιντερφερονης τυπου 1 | |
EA201590833A1 (ru) | Антитела для лечения и профилактики болезни альцгеймера и их применение | |
DE602006014691D1 (de) | DIAGNOSE, BEHANDLUNG UND PRÄVENTION VON GEFÄSSERKRANKUNGEN MITTELS IL-1alpha-AUTOANTIKÖRPERN | |
NZ595262A (en) | Use of il-23 and il-27 antagonists to treat autoimmune ocular inflammatory disease | |
UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
EA200971131A1 (ru) | Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам | |
WO2007033216A3 (en) | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state | |
UA99094C2 (ru) | Способ лечения пациента с системной красной волчанкой | |
BRPI0518993A2 (pt) | composto ou um sal, solvato ou Éster farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto | |
TW200716172A (en) | Pharmaceutical compositions for treating lower motor neuron diseases | |
RU2008116567A (ru) | Биомаркеры | |
Yang et al. | Computational discovery and experimental verification of tyrosine kinase inhibitor pazopanib for the reversal of memory and cognitive deficits in rat model neurodegeneration | |
ATE530667T1 (de) | Kcnn3 als diagnostisches und therapeutisches target für alzheimer-krankheit | |
ES2619569T3 (es) | Método de ensayo de infección o inflamación de las vías respiratorias inferiores |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |